{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T23:32:45Z","timestamp":1772580765759,"version":"3.50.1"},"reference-count":37,"publisher":"Japan Endocrine Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2014]]},"DOI":"10.1507\/endocrj.ej14-0115","type":"journal-article","created":{"date-parts":[[2014,8,13]],"date-time":"2014-08-13T23:57:04Z","timestamp":1407974224000},"page":"1105-1114","source":"Crossref","is-referenced-by-count":11,"title":["Retinoic acid receptor-\u03b1 up-regulates proopiomelanocortin gene expression in AtT20 corticotroph cells"],"prefix":"10.1507","volume":"61","author":[{"given":"Akira","family":"Uruno","sequence":"first","affiliation":[{"name":"Department of Medical Biochemistry, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Saito-Hakoda","sequence":"additional","affiliation":[{"name":"Department of Molecular Endocrinology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Department of Molecular Endocrinology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naotaka","family":"Kogure","sequence":"additional","affiliation":[{"name":"Department of Molecular Endocrinology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rehana","family":"Parvin","sequence":"additional","affiliation":[{"name":"Department of Molecular Endocrinology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Molecular Endocrinology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuko","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Molecular Endocrinology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Kudo","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Yoshikawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kagechika","sequence":"additional","affiliation":[{"name":"Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Tokyo 101-0062, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasumasa","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Health Service Center, Kochi University, Kochi 780-8520, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadayoshi","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Department of Molecular Endocrinology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Uruno A, Sugawara A, Kudo M, Sato M, Sato K, et al. (2003) Transcription suppression of thromboxane receptor gene expression by retinoids in vascular smooth muscle cells. <i>Hypertens Res<\/i> 26: 815-821.","DOI":"10.1291\/hypres.26.815"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Uruno A, Sugawara A, Kanatsuka H, Kagechika H, Saito A, et al. (2005) Upregulation of nitric oxide production in vascular endothelial cells by all-<i>trans<\/i> retinoic acid through the phosphoinositide 3-kinase\/Akt pathway. <i>Circulation<\/i> 112: 727-736.","DOI":"10.1161\/CIRCULATIONAHA.104.500959"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Saito A, Sugawara A, Uruno A, Kudo M, Kagechika H, et al. (2007) All-<i>trans<\/i> retinoic acid induces in vitro angiogenesis via retinoic acid receptor: possible involvement of paracrine effects of endogenous vascular endothelial growth factor signaling. <i>Endocrinology<\/i> 148: 1412-1423.","DOI":"10.1210\/en.2006-0900"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Uruno A, Noguchi N, Matsuda K, Nata K, Yoshikawa T, et al. (2011) All-<i>trans<\/i> retinoic acid and a novel synthetic retinoid tamibarotene (Am80) differentially regulate CD38 expression in human leukemia HL-60 cells: possible involvement of protein kinase C-&delta;. <i>J Leukoc Biol<\/i> 90: 235-247.","DOI":"10.1189\/jlb.0109025"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Flynn PJ, Miller WJ, Weisdorf DJ, Arthur DC, Brunning R, et al. (1983) Retinoic acid treatment of acute promyelocytic leukemia: in vitro and in vivo observations. <i>Blood<\/i> 62: 1211-1217.","DOI":"10.1182\/blood.V62.6.1211.1211"},{"key":"6","unstructured":"6. Lotan R (1996) Retinoids and their receptors in modulation of differentiation, development, and prevention of head and neck cancers. <i>Anticancer Res<\/i> 16: 2415-2419."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. P&aacute;ez Pereda M, Missale C, Gr&uuml;bler Y, Arzt E, Schaaf L, et al. (2000) Nerve growth factor and retinoic acid inhibit proliferation and invasion in thyroid tumor cells. <i>Mol Cell Endocrinol<\/i> 167: 99-106.","DOI":"10.1016\/S0303-7207(00)00286-0"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Soprano KJ, Purev E, Vuocolo S, Soprano DR (2006) Rb2\/p130 and protein phosphatase 2A: key mediators of ovarian carcinoma cell growth suppression by all-trans retinoic acid. <i>Oncogene<\/i> 25: 5315-5325.","DOI":"10.1038\/sj.onc.1209679"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Pasquali D, Rossi V, Bellastella G, Bellastella A, Sinisi AA (2006) Natural and synthetic retinoids in prostate cancer. <i>Curr Pharm Des<\/i> 12: 1923-1929.","DOI":"10.2174\/138161206776873554"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Schteingart DE (2009) Drugs in the medical treatment of Cushing&rsquo;s syndrome. <i>Expert Opin Emerg Drugs<\/i> 14: 661-671.","DOI":"10.1517\/14728210903413522"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Fleseriu M, Petersenn S (2012) Medical management of Cushing&rsquo;s disease: what is the future? <i>Pituitary<\/i> 15: 330-341.","DOI":"10.1007\/s11102-012-0397-5"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Nieman LK (2002) Medical therapy of Cushing&rsquo;s disease. <i>Pituitary<\/i> 5: 77-82.","DOI":"10.1023\/A:1022308429992"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Heaney AP, Fernando M, Yong WH, Melmed S (2002) Functional PPAR-&gamma; receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. <i>Nat Med<\/i> 8: 1281-1287.","DOI":"10.1038\/nm784"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. P&aacute;ez-Pereda M, Kovalovsky D, Hopfner U, Theodoropoulou M, Pagotto U, et al. (2001) Retinoic acid prevents experimental Cushing syndrome. <i>J Clin Invest<\/i> 108: 1123-1131.","DOI":"10.1172\/JCI11098"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Castillo V, Giacomini D, P&aacute;ez-Pereda M, Stalla J, Labeur M, et al. (2006) Retinoic acid as a novel medical therapy for Cushing&rsquo;s disease in dogs. <i>Endocrinology<\/i> 147: 4438-4444.","DOI":"10.1210\/en.2006-0414"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Pecori Giraldi F, Ambrogio AG, Andrioli M, Sanguin F, Karamouzis I, et al. (2012) Potential role for retinoic acid in patients with Cushing&rsquo;s disease. <i>J Clin Endocrinol Metab<\/i> 97: 3577-3583.","DOI":"10.1210\/jc.2012-2328"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Cho JH, Kwon IS, Kim S, Ghil SH, Tsai MJ, et al. (2001) Overexpression of BETA2\/NeuroD induces neurite outgrowth in F11 neuroblastoma cells. <i>J Neurochem<\/i> 77: 103-109.","DOI":"10.1046\/j.1471-4159.2001.t01-1-00230.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kim JW, Seghers V, Cho JH, Kang Y, Kim S, et al. (2002) Transactivation of the mouse sulfonylurea receptor I gene by BETA2\/NeuroD. <i>Mol Endocrinol<\/i> 16: 1097-1107.","DOI":"10.1210\/mend.16.5.0934"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Uruno A, Matsuda K, Noguchi N, Yoshikawa T, Kudo M, et al. (2011) Peroxisome proliferator-activated receptor-&gamma; suppresses <i>CYP11B2<\/i> expression and aldosterone production. <i>J Mol Endocrinol<\/i> 46: 37-49.","DOI":"10.1677\/JME-10-0088"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Leroy P, Nakshatri H, Chambon P (1991) Mouse retinoic acid &alpha;2 receptor isoform is transcribed from a promoter that contains a retinoic acid response element. <i>Proc Natl Acad Sci U S A<\/i> 88: 10138-10142.","DOI":"10.1073\/pnas.88.22.10138"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Lehmann JM, Zhang XK, Pfahl M (1992) RAR &gamma;2 expression is regulated through a retinoic acid response element embedded in Sp1 sites.<i> Mol Cell Biol<\/i> 12: 2976-2985.","DOI":"10.1128\/MCB.12.7.2976"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Umemiya H, Fukasawa H, Ebisawa M, Eyrolles L, Kawachi E, et al. (1997) Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers. <i>J Med Chem<\/i> 40: 4222-4234.","DOI":"10.1021\/jm9704309"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Poulin G, Turgeon B, Drouin J (1997) NeuroD1\/beta2 contributes to cell-specific transcription of the proopiomelanocortin gene. <i>Mol Cell Biol<\/i> 17: 6673-6682.","DOI":"10.1128\/MCB.17.11.6673"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Poulin G, Lebel M, Chamberland M, Paradis FW, Drouin J (2000) Specific protein-protein interaction between basic helix-loop-helix transcription factors and homeoproteins of the Pitx family. <i>Mol Cell Biol<\/i> 20: 4826-4837.","DOI":"10.1128\/MCB.20.13.4826-4837.2000"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Lamolet B, Pulichino AM, Lamonerie T, Gauthier Y, Brue T, et al. (2001) A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. <i>Cell<\/i> 104: 849-859.","DOI":"10.1016\/S0092-8674(01)00282-3"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Giacomini D, P&aacute;ez-Pereda M, Theodoropoulou M, Labeur M, Refojo D, et al. (2006) Bone morphogenetic protein-4 inhibits corticotroph tumor cells: involvement in the retinoic acid inhibitory action. <i>Endocrinology<\/i> 147: 247-256.","DOI":"10.1210\/en.2005-0958"},{"key":"27","unstructured":"27. Saito-Hakoda A, Uruno A, Shimizu K, Kudo M, Saito-Ito T, et al. (2012) Retinoid X receptor agonists differentially affect proliferation, apoptosis, and ACTH secretion\/POMC gene expression in AtT20 corticotroph cells. <i>Endocr Rev<\/i> 33: SAT-482 (Abstract)."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Sz&eacute;les L, P&oacute;liska S, Nagy G, Szatmari I, Szanto A, et al. (2010) Research resource: transcriptome profiling of genes regulated by RXR and its permissive and nonpermissive partners in differentiating monocyte-derived dendritic cells. <i>Mol Endocrinol<\/i> 24: 2218-2231.","DOI":"10.1210\/me.2010-0215"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Aghi MK (2008) Management of recurrent and refractory Cushing disease. <i>Nat Clin Pract Endocrinol Metab<\/i> 4: 560-568.","DOI":"10.1038\/ncpendmet0947"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Heaney AP (2003) Novel pituitary ligands: peroxisome proliferator activating receptor-&gamma;. <i>Pituitary<\/i> 6: 153-159.","DOI":"10.1023\/B:PITU.0000011176.05771.46"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Suri D, Weiss RE (2005) Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing&rsquo;s disease. <i>J Clin Endocrinol Metab<\/i> 90: 1340-1346.","DOI":"10.1210\/jc.2004-1746"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Mullan KR, Leslie H, McCance DR, Sheridan B, Atkinson AB (2006) The PPAR-&gamma; activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson&rsquo;s syndrome. <i>Clin Endocrinol (Oxf)<\/i> 64: 519-522.","DOI":"10.1111\/j.1365-2265.2006.02501.x"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Pulichino AM, Vallette-Kasic S, Tsai JP, Couture C, Gauthier Y, et al. (2003) Tpit determines alternate fates during pituitary cell differentiation. <i>Genes Dev<\/i> 17: 738-747.","DOI":"10.1101\/gad.1065703"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Tateno T, Izumiyama H, Doi M, Yoshimoto T, Shichiri M, et al. (2007) Differential gene expression in ACTH -secreting and non-functioning pituitary tumors. <i>Eur J Endocrinol <\/i>157: 717-724.","DOI":"10.1530\/EJE-07-0428"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Lamolet B, Poulin G, Chu K, Guillemot F, Tsai MJ, et al. (2004) Tpit-independent function of NeuroD1(BETA2) in pituitary corticotroph differentiation. <i>Mol Endocrinol<\/i> 18: 995-1003.","DOI":"10.1210\/me.2003-0127"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Oyama K, Sanno N, Teramoto A, Osamura RY (2001) Expression of neuro D1 in human normal pituitaries and pituitary adenomas. <i>Mod Pathol<\/i> 14: 892-899.","DOI":"10.1038\/modpathol.3880408"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Tahara S, Kurotani R, Ishii Y, Sanno N, Teramoto A, et al. (2002) A case of Cushing&rsquo;s disease caused by pituitary adenoma producing adrenocorticotropic hormone and growth hormone concomitantly: aberrant expression of transcription factors NeuroD1 and Pit-1 as a proposed mechanism. <i>Mod Pathol<\/i> 15: 1102-1105.","DOI":"10.1097\/01.MP.0000030451.28828.00"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/61\/11\/61_EJ14-0115\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T06:41:39Z","timestamp":1618296099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/61\/11\/61_EJ14-0115\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej14-0115","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}